title: Refractory dissecting Cellulitis of the Scalp Successfully controlled with Adalimumab.
abstract: Dissecting cellulitis of the scalp (DCS) is an uncommon inflammatory disease that often results in scarring alopecia. Numerous therapies have either proved ineffective or only temporarily effective in the management of this condition. Recent reports show adequate responses to tumor necrosis factor (TNF) inhibitors in cases of DCS. We report a case of severe recalcitrant DCS successfully treated with adalimumab.
authors.affiliation: Board Certified Dermatologist, Program Director of the University of Puerto Rico, Associate Professor of the University of Puerto Rico.
authors.forename: Rafael F
authors.initials: RF
authors.lastname: Martin-García
authors.affiliation: Board Certified Dermatologist, Private practice San Diego, California.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Rullán
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012074:Remission Induction; D012536:Scalp Dermatoses / Q000188:drug therapy*; D012873:Skin Diseases, Genetic / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab
keywords: Biologics; Hair disorders; Scarring alopecia; TNFα-inhibitors